Huperzine A in the treatment of alzheimer's disease and vascular dementia: A meta-analysis

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Xing, Shu Huai ^a   Zhu, Chun Xiao ^b   Zhang, Rui ^a   An, Li ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Shijingshan Center for Disease Prevention and Control   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; HUPERZINE A; PLACEBO;

ALZHEIMER DISEASE; COGNITION; CONSTIPATION; DAILY LIFE ACTIVITY; DIARRHEA; DIZZINESS; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; MEMORY; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NAUSEA; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

EID: 84896832064     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/363985     Document Type: Review

References (48)

1. Wang B. S., Wang H., Wei Z. H., Song Y. Y., Zhang L., Chen H. Z., Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. Journal of Neural Transmission 2009 116 4 457 465 2-s2.0-67349262023 10.1007/s00702-009-0189-x
2. Giacobini E., Invited review. Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochemistry International 1998 32 5-6 413 419 2-s2.0-0032078728 10.1016/S0197-0186(97)00124- 1 (Pubitemid 28287193)
3. Hansen R. A., Gartlehner G., Lohr K. N., Kaufer D. I., Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Drugs and Aging 2007 24 2 155 167 2-s2.0-33847274839 10.2165/00002512-200724020-00007 (Pubitemid 46327574)
4. Xu Z. Q., Liang X. M., Juan-Wu J. W., Zhang Y. F., Zhu C. X., Jiang X. J., Treatment with huperzine A improves cognition in vascular dementia patients. Cell Biochemistry and Biophysics 2012 62 1 55 58 2-s2.0-84855575027 10.1007/s12013-011-9258-5
5. Wang J., Zhang H. Y., Tang X. C., Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacologica Sinica 2009 30 7 879 888 2-s2.0-67651166807 10.1038/aps.2009.82
6. Xu S. S., Cai Z. Y., Qu Z. W., Yang R. M., Cai Y. L., Wang G. Q., Su X. Q., Zhong X. S., Cheng R. Y., Xu W. A., Li J. X., Feng B., Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Acta Pharmacologica Sinica 1999 20 6 486 490 2-s2.0-13044283042 (Pubitemid 29302406)
7. Kelley B. J., Knopman D. S., Alternative medicine and Alzheimer disease. Neurologist 2008 14 5 299 306 2-s2.0-53549104731 10.1097/NRL.0b013e318172cf4d
8. Little J. T., Walsh S., Aisen P. S., An update on huperzine A as a treatment for Alzheimer's disease. Expert Opinion on Investigational Drugs 2008 17 2 209 215 2-s2.0-39049152973 10.1517/13543784.17.2.209 (Pubitemid 351578201)
9. Zangara A., The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacology Biochemistry and Behavior 2003 75 3 675 686 2-s2.0-0043204247 10.1016/S0091-3057(03)00111-4 (Pubitemid 36939173)
10. Bai D. L., Tang X. C., He X. C., Huperzine A, A potential therapeutic agent for treatment of Alzheimer's disease. Current Medicinal Chemistry 2000 7 3 355 374 2-s2.0-0034098365 (Pubitemid 30396443)
11. Santaguida P. S., Raina P., Booker L., Patterson C., Baldassare F., Cowan D., Gauld M., Levine M., Unsal A., Pharmacological treatment of dementia. Evidence Report/Technology Assessment 2004 97 1 16 2-s2.0-3442890572
12. Chow T. W., Review: insufficient evidence on Huperzine A for Alzheimer's-commentary. Evidence-Based Mental Health 2008 11 4 112 2-s2.0-68849096296 10.1136/ebmh.11.4.112
13. Shi C. C., Lin D. H., Yu F., Meta-analysis of efficacy and safety of huperzine A for treatment of Alzheimer's disease. Chinese Journal of New Drugs and Clinical Remedies 2012 3 12 737 741
14. Li J., Wu H. M., Zhou R. L., Liu G. J., Dong B. R., Huperzine A for Alzheimer's disease. Cochrane Database of Systematic Reviews 2008 2 CD005592 2-s2.0-44949092629
15. Hao Z., Liu M., Liu Z., Lv D., Huperzine A for vascular dementia. Cochrane database of systematic reviews (Online) 2009 2 CD007365 2-s2.0-67549142955
16. McKhann G., Drachman D., Folstein M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984 34 7 939 944 2-s2.0-0021271971 (Pubitemid 14076461)
17. Roman G. C., Tatemichi T. K., Erkinjuntti T., Cummings J. L., Masdeu J. C., Garcia J. H., Amaducci L., Orgogozo J. M., Brun A., Hofman A., Moody D. M., O'Brien M. D., Yamaguchi T., Grafman J., Drayer B. P., Bennett D. A., Fisher M., Ogata J., Kokmen E., Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993 43 2 250 260 2-s2.0-0027534657 (Pubitemid 23060253)
18. Review Manager (RevMan) [Computer program],. Version 5. 0.Copenhagen: the Nordic Cochrane Centre, The Cochrane Collaboration, 2008
19. Liu M., Tang L. Q., Li J., The effect observation of Alzheimer treated with Huperzine A. China Medical Herald 2011 8 13 28 30
20. Yang C., Huperzine A in the treatment of Alzheimer's disease, analysis of clinical effect. North China Coal Medical University 2009 11 3 383 384
21. Yang J., Shi L., Tian S., Huperzine A in the treatment of mild to moderate dementia, a clinical observation. Beijing Medical Journal 2008 30 1 61
22. Chen M. J., Gao Z. X., Deng H. Y., A multi-center, double-blind clinical trial of huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Chinese Journal of New Drugs and Clinical Remedies 2000 1 19 10 12
23. Zhang R. W., Tang X. C., Han Y. Y., Sang G. W., Zhang Y. D., Ma Y. X., Zhang C. L., Yang R. M., Drug evaluation of huperzine A in the treatment of senile memory disorders. Acta Pharmacologica Sinica 1991 12 3 250 252 2-s2.0-0025763629
24. Aisen P. S., A multi-center, double-blind, placebo-controlled therapeutic trial to determine whether natural Huperzine A improves cognitive function. NCT00083590, 2004, http://www.clinicaltrials.gov
25. Wang W., Wang L. N., Zhou B., Zhang X. H., Effect of huperzine A on memory function of patients with mild cognitive impairment. Chinese Journal of Clinical Rehabilitation 2005 9 8 23 25 2-s2.0-20544470159 (Pubitemid 40846618)
26. Ding S. J., Ni Y. H., Li J. S., Effectiveness of Huperzine A, Nimodipine and the combinative utilization to age associated memory impairment and influence of those to levels of plasma total antioxidant capacity and calcium of platelet. Journal of Clinical Neurology 2009 22 2 130 132 2-s2.0-68149137542
27. Yin F. M., Du Y. Y., Wang L. E., The effect of Huperzine A for patients with vascular dementia. Modern Rehabilitation 2001 5 11 74 75
28. Shang X. Y., Wang Y., Cui Q. H., The clinical observation of Haboyin (Huperzine A) in the treatment of vascular dementia. Hei Long Jiang Medical Journal 2003 27 3 203
29. Zhong Z. G., Liang K. Z., Clinical observation of huperzine A in the treatment of nineteen patients with vascular dementia. Journal of Hainan Medical College 2004 10 4 251 252
30. Song Z. X., Tian X. J., Huperzine A improve cognitive function from multiple infarcts dementia. Chinese Community Doctors 2008 10 15 28
31. Yan G. L., Li C. W., Nie H. L., The effect of conventional therapy plus Huperzine A for vascular dementia. People's Military Surgeon 2008 51 4 218 219
32. Fan W. N., The clinical observation of Huperzine A plus nimodipine for mild to moderate vascular dementia. Prevention and Treatment of Cardio-Cerebral-Vascular Diseases 2009 9 3 216 217
33. Weng Q. L., Du J. B., Lu C. H., Evaluation on the therapeutic efficacy of Xinnao Shutong Capsule combined with Huperzine A on the patients with vascular dementia. Shanghai Medical and Pharmaceutical Journal 2010 31 12 568 570
34. Ren L., Du J. B., Weng Q. L., Evaluation on the therapeutic efficacy of different doses of Huperzine A on the patients with vascular dementia. Journal of Clinical Neuroscience 2010 18 6 644 646
35. Yang C. Y., Lü Z. P., Zheng C. G., Efficacy and reliability of Huperzine A in mild and moderate Alzheimer's disease. Chinese Journal of Clinical Rehabilitation 2003 7 31 4258 4259 2-s2.0-2442583539
36. Zhang M. L., Yuan G. Z., Yao J. J., Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer's disease. Chinese Journal of New Drugs and Clinical Remedies 2006 25 9 693 695
37. Shi B. H., Li Y. F., Li C. Y., Clincal study of huperzine A on patients with mild and moderate Alzheimer disease. Practical Pharmacy and Clinical Remedies 2013 16 1 37 38
38. Xu S. S., Gao Z. X., Weng Z., Du Z. M., Xu W. A., Yang J. S., Zhang M. L., Tong Z. H., Fang Y. S., Chai X. S., Li S. L., Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacologica Sinica 1995 16 5 391 395 2-s2.0-0029112606
39. Zhang Z., Wang X., Chen Q., Shu L., Wang J., Shan G., Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Chinese Medical Journal 2002 82 14 941 944 2-s2.0-0037173785
40. Rafii M. S., Walsh S., Little J. T., Behan K., Reynolds B., Ward C., Jin S., Thomas R., Aisen P. S., A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011 76 16 1389 1394 2-s2.0-79955444505 10.1212/WNL.0b013e318216eb7b
41. Liu F. G., Fang Y. S., Gao Z. X., et al. Double-blind control treatment of huperzine-A and placebo in 28 patients with Alzheimer disease. Chinese Journal of Pharmacoepidemiol 1995 4 4 196 198
42. Chai X. S., Weng Z., Zhao C. Y., Shuang Yi Ping in treatment Alzheimer disease, a double-blind controlled study. Shanghai Medical & Pharmaceutical Journal 1998 1 16 17
43. Zhou B. R., Xu Z. Q., Kuang Y. F., Deng Y. H., Liu Z. F., Effectiveness of polydrug therapy for senile dementia. Chinese Journal of Clinical Rehabilitation 2004 8 7 1214 1215 2-s2.0-2442495030
44. Isaac M. G., Quinn R., Tabet N., Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2008 3 CD002854 2-s2.0-53749093780
45. Sun Q. Q., Xu S. S., Pan J. L., Guo H. M., Cao W. Q., Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Acta Pharmacologica Sinica 1999 20 7 601 603 2-s2.0-0032856585
46. Ha G. T., Wong R. K., Zhang Y., Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies. Chemistry and Biodiversity 2011 8 7 1189 1204 2-s2.0-79960600801 10.1002/cbdv.201000269
47. Masaki K. H., Losonczy K. G., Izmirlian G., Foley D. J., Ross G. W., Petrovitch H., Havlik R., White L. R., Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000 54 6 1265 1272 2-s2.0-0034724365 (Pubitemid 30174045)
48. Vickers A., Goyal N., Harland R., Rees R., Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clinical Trials 1998 19 2 159 166 2-s2.0-0032054651 10.1016/S0197-2456(97)00150- 5 (Pubitemid 28191970)